^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    segigratinib (3D185)

    i
    Other names: 3D185, HH185 , 3D-185, HH 185, HH-185, 3D 185
    Associations

    News

    Trials
    Company:
    3DMed, HaiHe Biopharma
    Drug class:
    CSF-1R inhibitor, FGFR1 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    A Monotherapy in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, 3D Medicines (Beijing) Co., Ltd. | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    segigratinib (3D185)
    7ms
    Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, 3D Medicines (Beijing) Co., Ltd. | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    segigratinib (3D185)
    over1year
    A Monotherapy in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, 3D Medicines (Beijing) Co., Ltd. | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    segigratinib (3D185)
    2years
    Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, 3D Medicines (Beijing) Co., Ltd. | Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    segigratinib (3D185)
    over2years
    Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, 3D Medicines (Beijing) Co., Ltd. | Trial completion date: Dec 2026 --> Jun 2024 | Trial primary completion date: Dec 2026 --> Dec 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    segigratinib (3D185)
    4years
    Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, 3D Medicines (Beijing) Co., Ltd.
    Clinical • New P2 trial
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    segigratinib (3D185)